Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms.


Journal

Journal of gynecologic oncology
ISSN: 2005-0399
Titre abrégé: J Gynecol Oncol
Pays: Korea (South)
ID NLM: 101483150

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 30 08 2019
accepted: 05 09 2019
pubmed: 4 12 2019
medline: 31 3 2021
entrez: 3 12 2019
Statut: ppublish

Résumé

The Fourth Edition of the Guidelines for Treatment of Uterine Body Neoplasm was published in 2018. These guidelines include 9 chapters: 1. Overview of the guidelines, 2. Initial treatment for endometrial cancer, 3. Postoperative adjuvant therapy for endometrial cancer, 4. Post-treatment surveillance for endometrial cancer, 5. Treatment for advanced or recurrent endometrial cancer, 6. Fertility-sparing therapy, 7. Treatment of uterine carcinosarcoma and uterine sarcoma, 8. Treatment of trophoblastic disease, 9. Document collection; and nine algorithms: 1-3. Initial treatment of endometrial cancer, 4. Postoperative adjuvant treatment for endometrial cancer, 5. Treatment of recurrent endometrial cancer, 6. Fertility-sparing therapy, 7. Treatment for uterine carcinosarcoma, 8. Treatment for uterine sarcoma, 9. Treatment for choriocarcinoma. Each chapter includes overviews and clinical questions, and recommendations, objectives, explanation, and references are provided for each clinical question. This revision has no major changes compared to the 3rd edition, but does have some differences: 1) an explanation of the recommendation decision process and conflict of interest considerations have been added in the overview, 2) nurses, pharmacists and patients participated in creation of the guidelines, in addition to physicians, 3) the approach to evidence collection is listed at the end of the guidelines, and 4) for clinical questions that lack evidence or clinical validation, the opinion of the Guidelines Committee is given as a "Recommendations for tomorrow".

Identifiants

pubmed: 31789001
pii: 31.e18
doi: 10.3802/jgo.2020.31.e18
pmc: PMC6918887
doi:

Types de publication

Journal Article Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Pagination

e18

Informations de copyright

Copyright © 2020. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.

Déclaration de conflit d'intérêts

No potential conflict of interest relevant to this article was reported.

Références

Gan To Kagaku Ryoho. 2002 Jun;29(6):1047-54
pubmed: 12109445
Int J Clin Oncol. 2010 Dec;15(6):531-42
pubmed: 21069552
Gan To Kagaku Ryoho. 2002 Jun;29(6):970-7
pubmed: 12109450
Int J Clin Oncol. 2016 Jun;21(3):419-34
pubmed: 27116188
J Gynecol Oncol. 2017 Mar;28(2):e32
pubmed: 28198168

Auteurs

Wataru Yamagami (W)

Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan. gami@z8.keio.jp.

Mikio Mikami (M)

Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa, Japan.

Satoru Nagase (S)

Department of Obstetrics and Gynecology, Faculty of Medicine, Yamagata University, Yamagata, Japan.

Tsutomu Tabata (T)

Department of Obstetrics and Gynecology, Tokyo Women's Medical University, Tokyo, Japan.

Yoichi Kobayashi (Y)

Department of Obstetrics and Gynecology, Kyorin University Faculty of Medicine, Tokyo, Japan.

Masanori Kaneuchi (M)

Department of Gynecology, Otaru General Hospital, Hokkaido, Japan.

Hiroaki Kobayashi (H)

Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University, Kagoshima, Japan.

Hidekazu Yamada (H)

Department of Gynecology, Miyagi Cancer Center, Miyagi, Japan.

Kiyoshi Hasegawa (K)

Department of Obstetrics and Gynecology, Dokkyo Medical University, Tochigi, Japan.

Hiroyuki Fujiwara (H)

Department of Obstetrics and Gynecology, Jichi Medical University, Tochigi, Japan.

Hidetaka Katabuchi (H)

Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Daisuke Aoki (D)

Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan. gami@z8.keio.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH